Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:VSTM

Verastem Q3 2026 Earnings Date & Estimates

Verastem logo
$10.04 -0.02 (-0.20%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$10.13 +0.09 (+0.93%)
As of 10/23/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Verastem is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Verastem in Q3 2026

Verastem is expected to post earnings of -$0.44 per share on revenue of $26.58 million. In the same quarter a year earlier Verastem reported -$1.35 per share on revenue of $11.24 million. Verastem last reported on August 6, 2026, posting -$0.35 per share and beating the -$0.4305 consensus estimate. Verastem has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.44
Expected Revenue
$26.58 million
Prior-Year EPS
-$1.35
Prior-Year Revenue
$11.24 million
Expected Revenue Growth
+136.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.35 (Beat by +$0.0805)
Last Quarter Revenue
$40.08 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Verastem Q3 2026 Earnings FAQ

Verastem (NASDAQ:VSTM) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Verastem's Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Verastem to post earnings of -$0.44 per share for Q3 2026.

The consensus revenue estimate for Verastem is $26.58 million for Q3 2026.

Verastem Earnings Headlines

Verastem consensus price target increased by 17.42% to $17.57
October 23 at 12:05 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/verastem-consensus-price-target-increased-by-17-42-to-17-57/ar-AA2fUkSB
What Verastem (VSTM)'s Trial Update Means For Shareholders
October 23 at 12:05 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/verastem-vstm-trial-means-shareholders-021041248.html
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.tc pixel
October 24 at 1:00 AM  |  The Oxford Club (Ad)
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
October 22 at 7:30 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261022618570/en/verastem-oncology-to-report-third-quarter-2026-financial-results-on-november-5-2026/
Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), BioNTech SE (BNTX)
October 21 at 7:16 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8267998/analysts-are-bullish-on-these-healthcare-stocks-verastem-vstm-biontech-se-bntx/
Verastem (NASDAQ:VSTM) Stock Price Expected to Rise, Mizuho Analyst Says
October 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31129761
See More Verastem Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verastem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verastem and other key companies, straight to your email.

About Verastem

Verastem (NASDAQ:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company’s research is centered on tumors driven by abnormalities in the RAS/MAPK signaling pathway, which can promote cancer-cell growth and resistance to treatment.

Verastem’s leading product candidates include avutometinib, an oral RAF/MEK clamp designed to inhibit signaling within the RAS/MAPK pathway, and defactinib, an oral focal adhesion kinase inhibitor. The company has studied these therapies individually and in combination for cancers including low-grade serous ovarian cancer, colorectal cancer, non-small cell lung cancer and pancreatic cancer. Its programs are intended to address cancers with limited treatment options and may be evaluated alongside other targeted or standard therapies.

Founded in 2010, Verastem is headquartered in Needham, Massachusetts, and conducts its research and development activities primarily through collaborations, clinical studies and regulatory programs in the United States and other international markets. The company is led by Dan Paterson, who serves as president and chief executive officer.

View Verastem Profile
Earnings Tools